MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
Pacira BioSciences Retained Earnings 2011-2026 | PCRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -206 M | -107 M | -149 M | -212 M | - | -399 M | -388 M | -389 M | -346 M | -308 M | -310 M | -296 M | -233 M | -180 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -107 M | -399 M | -271 M |
Quarterly Retained Earnings Pacira BioSciences
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -196 M | -199 M | -201 M | -206 M | -202 M | -206 M | -222 M | -78.9 M | -97.8 M | -107 M | -132 M | -143 M | -168 M | -149 M | -139 M | - | -158 M | -212 M | -207 M | -224 M | -244 M | -254 M | -254 M | -254 M | -254 M | -399 M | -399 M | -399 M | -399 M | -388 M | -388 M | -388 M | -388 M | -389 M | -389 M | -389 M | -389 M | -346 M | -346 M | -346 M | -346 M | -308 M | -308 M | -308 M | -308 M | -310 M | -310 M | -310 M | -310 M | -296 M | -296 M | -296 M | -296 M | -233 M | -233 M | -233 M | -233 M | -180 M | -180 M | -180 M | -180 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -78.9 M | -399 M | -265 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.64 | -1.12 % | $ 1.36 B |  Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
-157 M | $ 40.9 | 0.91 % | $ 1.5 B | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 4.36 | 4.06 % | $ 61.3 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-183 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Solid Biosciences
SLDB
|
-958 M | $ 7.13 | -1.79 % | $ 624 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.65 | -1.22 % | $ 2.06 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.13 | 1.8 % | $ 122 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 1.2 | 9.09 % | $ 1.49 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.48 | 1.16 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
-2.42 B | $ 6.16 | -1.28 % | $ 3.81 B | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
Veru
VERU
|
-295 M | $ 2.26 | 0.44 % | $ 305 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 5.33 | -1.11 % | $ 344 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.41 | 3.68 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.47 | 2.67 % | $ 434 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.57 | 9.36 % | $ 338 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-182 M | $ 0.87 | 0.14 % | $ 3.75 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 18.47 | 0.22 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 7.64 | 1.6 % | $ 302 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.99 | 6.48 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 15.04 | 0.67 % | $ 18.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-300 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-403 M | $ 0.89 | 1.29 % | $ 32 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-47.2 M | $ 0.53 | -2.39 % | $ 2.27 M |  China |
 |
TherapeuticsMD
TXMD
|
-952 M | $ 2.07 | 1.47 % | $ 23.9 M | USA |